Verywell Health on MSN
What happens to weight loss and muscle growth when you take creatine
Medically reviewed by Allison Herries, RDN Key Takeaways Creatine is a safe and effective supplement for healthy adults to ...
The European Commission approved a high-dose Spinraza regimen for people with 5q spinal muscular atrophy (SMA). The updated regimen includes higher loading doses followed by higher maintenance dosing.
Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize durability and outcomes, particularly in undertreated patients. This segment ...
The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...
What Is Uplizna, and Why Does It Matter? Uplizna (inebilizumab-cdon) is a prescription medicine recently approved by the FDA to treat adults with generalized myasthenia gravis (gMG) who test positive ...
Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available. In a phase 2a, double-blind, randomized trial, we assigned healthy ...
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches Fig 1. Study schema of the GENTLE-Z trial. Patients with previously untreated, CLDN18.2-positive, ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products (CHMP) recommended approval for a high dose of Biogen's antisense oligonucleotide Spinraza (nusinersen) to treat spinal ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved ...
Coca-Cola has taken another stab at artificial-intelligence-generated holiday ads after last year’s attempts drew criticism from creative professionals over their execution and the technology’s ...
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional benefit in slowing disability progression compared with the standard ...
Sept 23 (Reuters) - The U.S. Food and Drug Administration has declined to approve a higher-dose version of Biogen's (BIIB.O), opens new tab drug for a rare genetic disorder that causes progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results